LinkedIn
WebsiteIntroduction
Aclarion Inc (NASDAQ: ACON) is a healthcare technology company headquartered in Broomfield, Colorado. The firm integrates magnetic resonance spectroscopy (MRS) with a proprietary augmented-intelligence algorithm to deliver software-as-a-service (SaaS) solutions aimed at noninvasively identifying markers of chronic low back and neck pain. Its initial offering focuses on providing physicians with diagnostic insights to support clinical decision-making.
Corporate Structure
Founded as a privately held enterprise, Aclarion completed its initial public offering and trades on the Nasdaq under the ticker ACON. The company operates with a workforce of 11–50 employees. The leadership team possesses experience in medical imaging, machine learning, and clinical diagnostics. The board of directors defines strategic objectives, including recent efforts to maintain compliance with Nasdaq's continued listing standards.
Chronic Pain by Joyce Hankins
Developments and News
- March 28, 2025: Aclarion executed a 1-for-27 reverse stock split to raise its per-share price above the $1.00 minimum required by Nasdaq. No fractional shares were issued; fractional interests were rounded up at the participant level.
- July 21, 2025: Filed a Form 8-K (Item 5.07), reporting developments related to its audited financial statements.
- August 14, 2025: Submitted its Form 10-Q for the quarter ended June 30, 2025, detailing operational results and balance sheet positions.
- September 3, 2025: Filed a Form 8-K covering material agreements, management changes, and Regulation FD disclosures.
- October 10, 2025: Participated in the International Spine and Pain Neurosurgery (ISPN) meeting, contributing to a session on MR spectroscopy and discogenic pain biomarkers.
- October 2025: Announced the retirement of CFO John Lorbiecki, who has guided financial strategy.
Financial and Strategic Analysis
As of October 13, 2025, Aclarion’s share price was $10.87, representing a 26.44% increase on a trading volume of 651,227 shares. Key metrics (trailing twelve months) include:
- Market capitalization: approximately $5.0 million
- Revenue: $62,950
- Net loss: $7.06 million
- Price-to-sales ratio: 69.2
- Price-to-book ratio: 0.31
- Return on assets: –44.35%
- Return on equity: –88.35%
- Cash and equivalents: $12.86 million
- Free cash flow: –$3.93 million
The continued net loss reflects ongoing investment in research and development and commercialization efforts for its Nociscan platform. The reverse stock split is intended to help meet listing requirements and may broaden interest from institutional investors. Cash reserves are expected to support product validation studies and regulatory engagements.
Market Position and Industry Context
Aclarion operates at the intersection of advanced imaging and digital diagnostics within the chronic pain management market. Its SaaS-based approach to interpreting MRS data distinguishes it from traditional hardware-centric competitors. The low back and neck pain sector represents a significant market opportunity, characterized by unmet diagnostic needs. The adoption of augmented-intelligence tools is increasing in medical equipment manufacturing; however, Aclarion is in an early commercial stage, pending broader reimbursement and clinical validation.
tl;dr
On March 28, 2025, Aclarion completed a 1-for-27 reverse split to maintain its Nasdaq listing. Regulatory filings in July, August, and September 2025 outlined material agreements, financial results, and management updates. The company’s share price rose to $10.87 (+26.44%) on October 13, 2025, supported by high trading volume. Participation in the ISPN session on October 10 demonstrated engagement with the spine-pain research community. Looking ahead, Aclarion will focus on the commercial rollout of its Nociscan diagnostic platform and securing reimbursement pathways in the chronic low back pain market.
